Institut Jean Paoli & Irène Calmettes;Université d'Aix-Marseille;INSERM (Institut National de la Santé et de la Recherche Médicale);GlaxoSmithKline Intellectual Property Development Limited;Centre
发明人:
申请号：
EP19182007.5
公开号：
EP3572432A1
申请日:
2016.01.26
申请国别(地区):
EP
年份:
2019
代理人:
摘要：
The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell； stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO:1； SEQ ID NO:2； SEQ ID NO:3； SEQ ID NO:4； SEQ ID NO:5； and/or SEQ ID NO:6.
